EUCTR2011-003564-72-DK进行中（未招募）1 期
A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. or 2. line chemotherapy to patients with HER2 negative local metastatic breastcancer. - XeNa
Aarhus University Hospital0 个研究点目标入组 110 人开始时间: 2012年1月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients with relaps of breastcancer with WHO performance status equal to or under 2. Life time more than 16 weeks. age 18 years and older.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Earlier treatment with Navelbine or Xeloda. Patients not able to swallow tablets.
- •CNS metastases.
- •Insufficient bone marrow or liver funktion.
研究者
相似试验
进行中（未招募）
不适用
Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium. - JASINT 1Histologically confirmed diagnosis of locally advanced or metastatic predominantly transitional cell carcinoma of the urothelium (TCCU) [urinary bladder, kidney, renal pelvis, or ureter]MedDRA version: 9.1Level: LLTClassification code 10044412EUCTR2010-020620-22-ITPIERRE FABRE MEDICAMENT68
撤回
2 期
Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium10004994bladder cancerNL-OMON36397Pierre Fabre5
进行中（未招募）
不适用
phase II study assessing the combination of Vinflunine with Gemcitabine versus Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic bladder cancerEUCTR2010-020620-22-DEPIERRE FABRE MEDICAMENT68
进行中（未招募）
不适用
phase II study assessing the combination of Vinflunine with Gemcitabine versus Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic bladder cancerEUCTR2010-020620-22-BEPIERRE FABRE MEDICAMENT68
进行中（未招募）
不适用
phase II study assessing the combination of Vinflunine with Gemcitabine versus Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic bladder cancerThe trial concerns patients suffering from advanced or metastatic Transitional Cell Carcinoma of the Urothelium (TCCU) who are unfit for Cisplatin-containing first-line treatment due to reduced renal function (GFR 30-60 mL/min) or due to reduced cardiac function (NYHA II-III)MedDRA version: 14.1Level: LLTClassification code 10046722Term: Urothelial carcinoma bladder stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020620-22-ATPIERRE FABRE MEDICAMENT68